Table II.

Immunogenicity of vaccinia virus-derived HLA-A*1101-restricted peptides in different mouse strains

HLA-A11 Potential Vaccinia Virus EpitopesHLA-A11/Kb (CD8+/LPS blasts) (n = 2)Av. Net SFCs/106 Cellsa
PeptideSequence% of peptide responseAv. net SFCs/106 cellsHLA-A11/Kb−/− (CD8+/LPS blasts) (n = 2)CB6F1 (CD8+/LPS blasts) (n = 2)Kb−/−Db−/− (CD8+/LPS blasts) (n = 2)CBA/J (CD8+/LPS blasts) (n = 2)
I3L (116–124)AVYGNIKHK1682565
E7R (130–138)STLNFNNLR1578b
A10L (171–180)NTYLFNILYK57287469
A47L (139–148)AFEFINSLLK11.55845
Vaccinia-infected target cellsNA11251455110043820
  • a NetSFCs/106 cells are calculated according to the formula: [(number of spots against relevant peptide − (number of spots against irrelevant peptides (HCV core 132)] × [(1 × 106)/number of effector cells/well]. Sample SFCs control irrelevant A11-peptide (Human Mage 3 69). NA, Not applicable. (−) indicates <20 SFCs/106 cells.

  • b Control irrelevant peptide were on average 20 SFCs/106 cells for HLA-A11/Kb, 15 for HLA-A11/Kb knockout, 15 for CB6F1; 14 for Kb−/−Db−/−, and 57 for CBA/J.